SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the initiation of an investigator-sponsored trial of vosaroxin in combination with azacitidine in patients with myelodysplastic syndrome (MDS). The trial is being conducted at the Washington University School of Medicine under the direction of Meagan A. Jacoby, M.D., Ph.D., Instructor of Medicine, Division of Oncology.
Help employers find you! Check out all the jobs and post your resume.